The University of Ottawa Heart Institute (UOHI) is using Affymetrix’s Genome-Wide Human single nucleotide polymorphism (SNP) Array 6.0 for its whole-genome association study on coronary artery disease (CAD).
Over the next three years, researchers at UOHI will use its solutions to screen the DNA of more than 12,000 individuals to confirm their findings, and also identify associations to provide scientists with an understanding of how to identify and develop personalized treatments for the causes of CAD, according to the Santa Clara, Calif.-based Affymetrix.
With the SNP Array 6.0, Affymetrix said the researchers are able to use a single, whole-genome panel to analyze larger, multiple sample sets for both the initial scan and replication phases of an association study. Traditionally, scientists have performed genome scans using a high-density, whole-genome panel and validated the results across a larger sample population with technology that focused on a subset of SNPs.
Affymetrix said its integrated whole-genome panel approach increases the overall genetic power of the studies and further accelerates the gene discovery process by enabling different groups to combine the data from different populations and disorders with overlapping phenotypes.
The UOHI has three clinical floors (116 beds) offering specialized cardiac care.